Thomas Ulmer
Direttore/Membro del Consiglio presso Aravax Pty Ltd.
Profilo
Thomas Ulmer is a Non-Executive Director at Aravax Pty Ltd.
He was previously a Co-Managing Director at Immatics Biotechnologies GmbH from 2018 to 2020 and Head of Planning, Forecasting & Resource Allocation at Merck KGaA from 2012 to 2016.
He also served as Chief Financial Officer at Immatics NV.
Ulmer holds an MBA from the University of Giessen.
Posizioni attive di Thomas Ulmer
| Società | Posizione | Inizio |
|---|---|---|
Aravax Pty Ltd.
 Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Direttore/Membro del Consiglio | 01/11/2020 |
Precedenti posizioni note di Thomas Ulmer
| Società | Posizione | Fine |
|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Amministratore Delegato | 12/02/2020 |
| MERCK KGAA | Corporate Officer/Principal | 01/07/2016 |
| IMMATICS N.V. | Direttore Finanziario/CFO | - |
Formazione di Thomas Ulmer
| University of Giessen | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| IMMATICS N.V. | Health Technology |
| Aziende private | 2 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Health Technology |
- Borsa valori
- Insiders
- Thomas Ulmer
